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We present the case of a 60-year-old man who developed subacute neurologic changes, in
the setting of stage III non-Hodgkin's follicular lymphoma, and was treated with induction
chemotherapy, followed by a year of maintenance rituximab. Magnetic resonance imaging
of the brain with gadolinium was pathognomonic for progressive multifocal leukoence-
phalopathy (PML). He was treated with sequential plasmapheresis and intravenous
immunoglobulin with clinical improvement. A literature review of the diagnostic workup
of rituximab-induced PML was undertaken. This case and the literature review demon-
strate the important role of magnetic resonance imaging of the brain in diagnosis and
follow-up of rituximab-induced PML. Specific radiologic features in combination with
cerebrospinal fluid can be diagnostic and avoid the morbidity and mortality of a diagnostic
brain biopsy. Plasmapheresis and intravenous immunoglobulin have a therapeutic role
and demonstrate symptom improvement and disease control. Follow-up imaging in
combination with clinical response is important in demonstrating a treatment response.
© 2016 the Authors. Published by Elsevier Inc. under copyright license from the University
of Washington. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).eview and publication of his case and radiologic images.
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Fig. 1 e Sagittal section of MRI of the brain (T2 weighted)
demonstrates hyperintense signal in the right
frontotemporal white matter.
R a d i o l o g y C a s e R e p o r t s 1 1 ( 2 0 1 6 ) 2 5 1e2 5 4252Introduction
First described in 1958 by Astrom et al. [1], progressive
multifocal leukoencephalopathy (PML) is a rare infectious
disease of the central nervous system caused by the John
Cunningham virus (JCV). Approximately 50% of the adult
population are asymptomatic carriers of the JCV [2]. However,
immunocompromised persons can develop disseminated ce-
rebral infection. The virus targets oligodendrocytes and as-
trocytes causing cell lysis [3], ultimately resulting in
demyelination. The first cases of PML were described in pa-
tients with hematologic malignancies, autoimmune condi-
tions, and immunocompromised states. Throughout the 80s,
PMLwas considered an AIDS-defining illness. With the advent
of immunomodulatory therapy in the last 2 decades, the
incidence of PML is rising.
Rituximab is an anti-CD20monoclonal antibody therapy [3]
licensed for use in follicular lymphoma, diffuse large B-cell
Non Hodgkins lymphoma, and chronic lymphocytic leukemia.
It is also used in autoimmune conditions such as severe
rheumatoid arthritis, Wegener granulomatosis, and micro-
scopic polyangiitis. Rituximab was first licensed in the US
Food and Drug Administration in 1997, followed by European
Union equivalents 1 year later [4]. The incidence of rituximab-
associated PML has been quoted at 1 of 30,000 cases in 1
review [3]. It is likely that the risk of developing PML also
depends on the patient's underlying diagnosis and may be
higher on those with lymphoproliferative disorders.Fig. 2 e Transverse section of MRI of the brain (T2 weighted
with gadolinium) demonstrates hyperintense signal in the
right frontotemporal white matter.Case report
We report the case of a 60-year-old man presenting with
subacute personality change, speech and attention deficits in
the setting of stage III non-Hodgkin's follicular lymphoma
treatedwith 6 cycles of RCHOP (rituximab, cyclophosphamide,
doxorubicin, vincristine, and prednisolone) chemotherapy
followed by a year of maintenance rituximab. He presented in
October 2013 with enlarging right inguinal lymph nodes.
Computed tomography of thorax, abdomen, and pelvis
revealed bilateral inguinal adenopathy. Biopsy of inguinal
lymph node demonstrated follicular lymphoma. He received 6
months of RCHOP chemotherapy and continued on mainte-
nance rituximab for another 6 months.
Four months after completion of his rituximab, he
presented with fatigue, personality change, and short-term
memory impairment on a background of a high-functioning
baseline. This was associated with apraxia of the upper
limbs, ataxia, and right upper limb tremor. On admission to
the hospital, he was noted to have aprosody, perseveration of
speech and left cortical inattention. On objective cognitive
testing in the form of an Montreal Cognitive Assessment, he
scored 25 of 30 with deficits reflecting temporofrontal
dysfunction. At this point, he had been symptomatic for
approximately 6 months. Screening for tuberculosis, Chla-
mydia pneumoniae, cryptococcal antigen, syphilis, Coxiella bur-
netii, hepatitis, HIV, and CreutzfeldteJakob disease was
negative.Magnetic resonance imaging (MRI) brain with gadolinium
showed T2 hyperintense signal in the frontotemporal white
matter on the right which decussated across the brainstem to
involve the contralateral medulla (Figs. 1 and 2). There was
no enhancement, and there was a lack of mass effect.
The patient's cerebrospinal fluid (CSF) returned as polymerase
chain reaction positive for JCV. The gold standard for diag-
nosis is a brain biopsy; however, there is an associated 8.4%
risk of morbidity and a 2.9% risk of death [5]. As such, the
combination of JCV in the CSF and the characteristic imaging
confirmed the diagnosis of PML.
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exchange followed by intravenous immunoglobulin for 5 days
with some improvement. Interval imaging suggests that the
lesions are stable in size. Clinically, there was improvement in
speech and memory which has been stable in follow-up at
1 year.Discussion
A literature review was undertaken accessing PubMed and
MEDLINE journals from 2009 to 2015 (Supplementary Table 1).
Papers were included if patients were in receipt of rituximab
therapy before PML diagnosis or symptoms had a confirmed
diagnosis of PML based on histologic examination or MRI and
CSF polymerase chain reaction positive JCV and no evidence
of HIV infection.
A total of 68 cases were included for the review with a
median age at diagnosis of 64 years. Underlying diagnoses
included B-cell lymphoproliferative disorders (58 patients),
systemic lupus erythematosus (2 patients), rheumatoid
arteritis (5 patients), chronic lymphocytic leukemia (1 patient),
autoimmune pancytopenia (1 patient), and idiopathic throm-
bocytopenic purpura (1 patient). In 62% (52/68) of cases, the
diagnosis was confirmed by MRI and JCV detection in the CSF.
Median time from last rituximab dose to PML diagnosis was
1.5 months.
The pathophysiology of rituximab-associated PML while
poorly understood relates to underlying viral reactivation
after rituximab and B-cell depletion. Pre-B cells can be infec-
ted with latent JCV. Immune dysregulation causes the virus
to be released into circulation to repopulate B-cells after
differentiation [4].
Clinical signs and symptoms are varied. Themost common
symptoms in PML related to rituximab use are confusion,
hemiparesis, incoordination, speech disturbance, and visual
problems [2]. There is no distinct treatment for this condition.
The monoclonal antibody agents can remain in the body for
many months after treatment has stopped; therefore, plasma
exchange is used to remove remaining drug from the system.
Mirtazapine has been used due to its serotonin receptor
blockade properties with variable results. Mefloquine has
been found to have anti-JCV activity; however, its efficacy has
yet to be determined [6].
An MRI of the brain with gadolinium in combination with
CSF can be diagnostic and avoid the morbidity and mortality
of a diagnostic brain biopsy. Typical radiologic features of
PML include multiple areas of white matter demyelination
do not conform to cerebrovascular territories, bilateral
changes, lack of mass effect or contrast enhancement,
decreased signal on T1-weighted images, and increased
signal on T2-weighted and fluid sequences [3,7]. Common
territories involved include the corpus callosum, brainstem,
pyramidal tracts, cerebellum, and periventricular and
subcortical areas [3,7]. Differentials for these findings
include HIV encephalopathy, primary CNS lymphoma,
stroke, brain tumor, CNS vasculitis, reversible posterior
leukoencephalopathy, varicella-zoster virus encephalopa-
thy, and multiple sclerosis (MS).The primary goal of management revolves around
restoring the host adaptive immune response, discontinuing
and starting plasma exchange PML and glucocorticoids [8].
Intravenous immunoglobulin (IVIG) and plasmapheresis
have been previously used in patients with MS treated with
natalizumab who developed PML. Dahlhaus et al. [9] reviewed
15 patients with MS who developed PML on natalizumab. Five
patientswere treatedwith plasmapheresis, 1 had IVIG 5 times,
and 9 patients had combination IVIG þ plasmapheresis. At a
median follow-up of 21.5months, none of the 15 patients died.
Twenty percent had mild disability, 60% had moderate
disability, and 20% had severe disability. The consensus
currently is that plasmapheresis with or without IVIG has the
potential to provide a therapeutic benefit in drug-induced
PML.
There are risk management guidelines for natalizumab
with regard to testing for JCV, assessing risk, informed
decision-making, and restricting prescription [2]. However,
given the significant clinical benefit versus the rarity of
rituximab-induced PML, there is at present no international
consensus on risk management of rituximab-induced PML.
Good practice should include education for physicians and
patients and reporting of all cases. An abstract presented at
American Society of Clinical Oncology of 26,597 noneHIV-
infected veterans with chronic lymphocytic leukemia who
developed PML demonstrated the rituximab increased the risk
of recurrence 19.9 (P < .05) [10]. The study authors proposed
serial measurement of JCV titers during long-term rituximab
therapy noneHIV-infected patients. Features associated with
survival include good performance status before diagnosis,
younger age, localized brain lesions onMRI, and a shorter time
from symptom onset to PML diagnosis [2].
In conclusion, rituximab-induced PML in the setting of a
previous Non Hodgkins lymphoma is extremely rare. Physi-
cians should have a high index of suspicion in patients pre-
senting with even minor neurologic symptoms as early
diagnosis and management can impact outcomes. MRI of the
brain with gadolinium is useful in diagnosing PML associated
with rare cases of immune dysregulation. Specific radiologic
features in combination with CSF can be diagnostic and avoid
the morbidity and mortality of a diagnostic brain biopsy.
Plasmapheresis and IVIG have a therapeutic role. The clinical
benefit of rituximab currently outweighs the risk of developing
PML; however, it should be discussed as part of a collaborative
decision-making process with patients. Currently, there is no
evidence for screening of JCV in this cohort.Supplementary data
Supplementary data associated with this article can be found
in the online version, at http://dx.doi.org/10.1016/j.radcr.2016.
06.003.r e f e r e n c e s
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